In EGFR-mutated advanced NSCLC, first line osimertinib plus platinum-pemetrexed prolonged overall survival versus monotherapy ...

The Trop-2 protein is highly expressed in EGFR -mutated NSCLC, and resistance to EGFR TKIs such as osimertinib is associated ...

Researchers at the University of Oslo and Oslo University Hospital have developed a promising new immunotherapy targeting the CTNNB1 gene mutation associated with various aggressive cancers such as ...

After being away from the team through the offseason, Colorado Buffaloes coach Deion Sanders opened up about his cancer diagnosis over the summer. Sanders and his medical team revealed he was battling ...

AURORA, Colo. (KDVR) — Dr. Ross Camidge is the director of the Thoracic Oncology Department at the University of Colorado Cancer Center on the Anschutz Medical Campus. “We’ve led or contributed to ...

CURE spoke with Dr. Xiuning Le during the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer. Lung cancer research has recognized the role of EGFR ...

A new analysis from the PALOMA-2 study presented today shows that subcutaneous administration of amivantamab every four weeks (Q4W), in combination with daily oral lazertinib, yields a high objective ...

A common artificial sweetener could make cancer treatments less effective, a new study has found. Sucralose, a sweetener found in many diet sodas, low-calorie snacks and powdered sugar substitutes, ...

"Choosing the first treatment for EGFR-mutated NSCLC is one of the most important decisions we make. It can influence how the disease progresses over time," said Joshua Bauml, M.D., Vice President, ...

Final overall survival (OS) results from the Phase III FLAURA2 trial demonstrate that first-line osimertinib plus chemotherapy significantly improves OS compared to osimertinib monotherapy in patients ...

BARCELONA, Spain, Sept. 6, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced new analyses from the Phase 3 MARIPOSA study showing that first-line treatment with RYBREVANT® (amivantamab ...

RYBREVANT® combination extends survival and significantly reduces common EGFR and MET resistance mutations seen with osimertinib-based treatment "Choosing the first treatment for EGFR-mutated NSCLC is ...